Lin BioScience (ROCO:6696) Debt-to-Asset : 0.02 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience Debt-to-Asset?

Lin BioScience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$13.48 Mil. Lin BioScience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$36.51 Mil. Lin BioScience's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was NT$2,198.31 Mil. Lin BioScience's debt to asset for the quarter that ended in Jun. 2023 was 0.02.

Lin BioScience Debt-to-Asset Historical Data

The historical data trend for Lin BioScience's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lin BioScience Debt-to-Asset Chart

Lin BioScience Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.01

Lin BioScience Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial										-	0.02	0.03	0.02	0.01

Competitive Comparison of Lin BioScience's Debt-to-Asset

For the Biotechnology subindustry, Lin BioScience's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lin BioScience's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lin BioScience's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Lin BioScience's Debt-to-Asset falls into.

Lin BioScience Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Lin BioScience's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(13.847	+	29.026)	/	3596.722
	=	0.01

Lin BioScience's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(13.484	+	36.51)	/	2198.307
	=	0.02

Lin BioScience (ROCO:6696) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Lin BioScience Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Lin BioScience's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Lin BioScience (ROCO:6696) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110

Website

https://www.linbioscience.com

Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience (ROCO:6696) Headlines

No Headlines